惟德精准完成超1.2亿元B轮融资，夯实软组织介入智能手术机器人领先地位

Core Viewpoint - Weide Precision Medical Technology Co., Ltd. has successfully completed a Series B financing round of over 120 million RMB, demonstrating strong market recognition of its technology and commercial capabilities [2][3]. Financing and Market Recognition - The Series B financing was led by Guangzhou Financial Holdings Fund and Guangzhou Tianhe Fund, with participation from several other investors, indicating confidence in the company's growth potential [2][3]. - The successful fundraising in a tightening financing environment highlights the capital market's acknowledgment of Weide's technological path and clinical value [3]. Product Development and Clinical Application - Weide Precision is the only domestic company mastering both intraoperative CT and ultrasound-based surgical robot technologies, enabling a wide range of applications in minimally invasive surgeries [3][4]. - The company's intraoperative CT-based surgical robot has been clinically applied in nearly 100 hospitals, achieving significant operational efficiency and safety [4]. - A new kidney intervention surgical robot based on intraoperative ultrasound technology is in the process of obtaining CE registration, aiming to be the first of its kind globally [6]. Global Expansion Strategy - Weide has established a "domestic validation + overseas expansion" model to strengthen its market position while collaborating with leading global medical enterprises [8]. - The company is focused on domestic production of key consumables to break the technological monopoly of foreign manufacturers, aligning with national policy directions [8]. Long-term Development Direction - The core development direction for surgical robots is intelligentization, transitioning from experience-driven to quantitative decision-making processes [10]. - Weide aims to enhance its position in the soft tissue intervention surgical robot field by continuously iterating its products through interdisciplinary teams [10]. Investor Insights - Investors recognize Weide's dual technology path as a significant advantage, accumulating comprehensive data and algorithms for interventional surgery [12]. - The focus on real clinical scenarios and the integration of imaging, algorithms, and robotic systems addresses long-standing operational challenges in percutaneous interventions [13]. - The company's ability to validate its technology in diverse clinical environments is seen as crucial for long-term success [14][15][16].